Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern
Recommend:
0

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
1m ago VISA : Wall Street Closing
4m ago HELLENIC BANK PUBLIC : Being green pays off
17m ago GENESEE & WYOMING : Connecticut seeking upgraded freight rail line
21m ago Argentine default looms as time runs out for debt deal
33m ago ALSTOM : Finishes Frame of Stator of 1st Generator Unit of Belo Monte
33m ago Nexans to Play Key Role at Qatar's New Refinery
33m ago MAXIM RESOURCES : Receives Reconnaissance Contract with ONHYM
33m ago EXILLON ENERGY : June Production Report
33m ago GeoPark Awarded New Exploratory License in Colombia
33m ago OIL SEARCH : Provides Updates on Taza Block
Latest news
Advertisement
Hot News 
EUROPLASMA : Annual Shareholders Meeting of 1st September, 2014
CHINA COMMERCIAL CREDIT : Issues Update on Recovery of Loan Guarantee Payments
DOTDIGITAL : Non-Executive Chairman's Trust Sells Shares (DIRECTOR DEALINGS)
NEWPARK RESOURCES : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
MAGELLAN HEALTH SERVICES : Reports Second Quarter 2014 Financial Results
Most Read News
1d ago FORD MOTOR : FBI investigates Ford engineer after listening devices found
1d ago APPLE : iPhones allow extraction of deep personal data, researcher finds
1d ago HILLSHIRE BRANDS : Tyson Foods to shut three factories, cut 950 jobs
1d ago AMAZON : far-reaching ambitions, lack of profits, unnerve investors
1d agoDJSTARBUCKS : Metro Money : Understanding the Economics of Iced Coffee
Most recommended articles
21m ago Argentine default looms as time runs out for debt deal
43m ago CREDIT SUISSE : Swiss banks face lower fines than feared in U.S. tax case
52m ago CAPITAL ONE FINANCIAL : Millhouse Capital says submits bid for Hypo
56m ago Argentina fails to reach breakthrough in debt mediator talks
57m ago Potential Argentine debt default looms as July 30 approaches
Dynamic quotes  
ON
| OFF